⌕
Kura Oncology · KURA · Nasdaq
Tenet 30 · Weak
Compare
$7.49+5.64%At closeTenet 30 · Weak
$7.49+0.40 (+5.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kura Oncology (KURA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KURA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 11:23 ET
Kura Oncology, Inc. (KURA) Presents at UBS Global Biopharma Conference 2026 Transcript

Kura Oncology, Inc. ( KURA ) UBS Global Biopharma Conference 2026 November 17, 2026 8:20 AM EST Company Participants Jennifer Fulk - Chief Financial Officer Brian Powl - Chief Commercial Officer Mollie Leoni - Chief Medi…

KURA +5.6% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 04:34 ET
Kura Oncology: Refills Drive Komzifti Launch, While Funding Bridge Sets The Pace

Kura Oncology is a BUY: KOMZIFTI uptake and a roughly $202 million enterprise value support a measured event-driven position. KOMZIFTI prescriptions outpaced new starts, suggesting growing refills; patient-level persiste…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireNov 13, 2026 · 12:33 ETCOMPANY'S OWN WORDS
Kura Oncology to Participate in Two Investor Conferences in November

SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the…

KURA +5.6% todayRead at source ↗
● Seeking AlphaNov 11, 2026 · 00:10 ET
Kura Oncology, Inc. (KURA) Q3 2026 Earnings Call Transcript

Kura Oncology, Inc. ( KURA ) Q3 2026 Earnings Call November 10, 2026 4:30 PM EST Company Participants Greg Mann - Senior Vice President of Investor Relations & Corporate Affairs Troy Wilson - Chairman, CEO & President Br…

KURA +5.6% todayRead at source ↗
● MarketBeatNov 10, 2026 · 20:15 ET
Kura Oncology Q3 Earnings Call Highlights

Kura Oncology NASDAQ: KURA reported third-quarter 2026 net product revenue of $13.9 million for leukemia treatment KOMZIFTI, up 53% from the prior quarter, as the company expanded prescribing accounts and prepared clinic…

KURA +5.6% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 18:20 ET
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.85 per share a year ago.…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the …

KURA +5.6% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 10:36 ET
Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Kura Oncology (KURA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2,…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:02 ETCOMPANY'S OWN WORDS
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 06:58 ETCOMPANY'S OWN WORDS
Kura Oncology to Report Third Quarter Financial Results on November 10

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 20…

KURA +5.6% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:06 ET
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know

Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

KURA +5.6% todayRead at source ↗
● MarketBeatOct 13, 2026 · 20:02 ET
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor

Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell ex…

KURA +5.6% todayRead at source ↗
● Seeking AlphaOct 13, 2026 · 19:52 ET
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript

Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 07:30 ET
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept stud…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireOct 7, 2026 · 07:15 ET
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, …

KURA +5.6% todayRead at source ↗
● Defense WorldSep 26, 2026 · 04:34 ET
Squarepoint Ops LLC Sells 78,432 Shares of Kura Oncology, Inc. $KURA

Squarepoint Ops LLC lessened its stake in shares of Kura Oncology, Inc. (NASDAQ: KURA) by 88.5% in a recent quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1…

KURA +5.6% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 13:51 ET
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneur…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 07:00 ET
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation –  SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 07:30 ET
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September …

KURA +5.6% todayRead at source ↗
● Zacks Investment ResearchSep 1, 2026 · 10:06 ET
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.…

KURA +5.6% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 07:15 ET
Kura Oncology to Participate in Three Investor Conferences in September

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at th…

KURA +5.6% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just KURA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.